The clinical relevance of DNMT1 and DACH1 requires further validation in larger, multicenter cohorts and preclinical therapeutic studies to provide a more comprehensive understanding of the DNMT1-DACH1 regulatory axis and its potential clinical applications in CRC patients. Here, DACH1 is linked to colorectal carcinoma.